Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism

Current Opinion in Hematology

Volumn 19, Issue 5, 2012, Pages 363-370

  Kearon, Clive ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

acquired; hereditary; thrombophilia; treatment; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S;

ANTICOAGULANT THERAPY; ANTITHROMBIN DEFICIENCY; CAUCASIAN; DISEASE ASSOCIATION; GENETIC RISK; HUMAN; MEDICAL DECISION MAKING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RARE DISEASE; REVIEW; THROMBOPHILIA; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HUMANS; MASS SCREENING; RISK ASSESSMENT; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84865438671     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e328356745b     Document Type: Review

References (41)

1. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. Br Med J 2011; 342:d3036.
2. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S-e494S.
3. Kyrle PA, Rosendaal FR, Eichinger S. Risk assessment for recurrent venous thrombosis. Lancet 2010; 376:2032-2039.
4. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. J Am Med Asooc 2009; 301:2472-2485.
5. Bezemer ID, Bare LA, Doggen CJ, et al. Gene variants associated with deep vein thrombosis. J Am Med Assoc 2008; 299:1306-1314. (Pubitemid 351439076)
6. Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120 000 cases and 180 000 controls. Thromb Haemost 2009; 102:360-370.
7. Delluc A, Gourhant L, Lacut K, et al. Association of common genetic variations and idiopathic venous thromboembolism. Results from EDITh, a hospital-based case-control study. Thromb Haemost 2010; 103:1161-1169.
8. Cohen D, Berger SP, Steup-Beekman GM, et al. Diagnosis and management of the antiphospholipid syndrome. Br Med J 2010; 340:c2541.
9. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376:1498-1509.
10. Middeldorp S. Is thrombophilia testing useful? Hematology Am Soc Hematol Educ Program 2011; 2011:150-155.
11. Cohn D, Vansenne F, de Borgie C, Middeldorp S. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev 2009; CD007069.
12. Sun X, Briel M, Busse JW, et al. Credibility of claims of subgroup effects in randomised controlled trials: systematic review. Br Med J 2012; 344:e1553.
13. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S-e43S.
14. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122:782-798.
15. Crowther MA, Ginsberg JS, Kearon C, et al. A randomized trial comparing 5mg and 10 mg warfarin loading doses. Arch Intern Med 1999; 159:46-48. (Pubitemid 29044118)
16. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e44S-e88S.
17. Wahlander K, Eriksson H, Lundstrom T, et al. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. Br J Haematol 2006; 133: 68-77. (Pubitemid 43327200)
18. Garcia DA, Khamashta MA, Crowther MA. How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood 2007; 110:3122-3127. (Pubitemid 350106302)
19. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome. N Engl J Med 2003; 349:1133-1138. (Pubitemid 37122325)
20. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of highintensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3:848-853. (Pubitemid 41632808)
21. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e152S-e184S.
22. Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008; 112:4432-4436.
23. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127:177-185. (Pubitemid 27332535)
24. Kearon C, Iorio A, Palareti G. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. J Thromb Haemost 2010; 8:2313-2315.
25. Kearon C. A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism. J Thromb Haemost 2012; 10:507-5011.
26. Douketis J, Tosetto A, Marcucci M, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010; 153:523-531.
27. Lijfering WM, Middeldorp S, Veeger NJ, et al. Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A. Circulation 2010; 121:1706-1712.
28. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108:313-318. (Pubitemid 36899022)
29. Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and noncarriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81:684-689. (Pubitemid 29216550)
30. Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77:624-628. (Pubitemid 27182953)
31. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362:523-526. (Pubitemid 36976716)
32. Christiansen SC, Cannegieter SC, Koster T, et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293:2352-2361. (Pubitemid 40676757)
33. Lijfering WM, Veeger NJ, Middeldorp S, et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood 2009; 114:2031-2036.
34. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104:332-338. (Pubitemid 28211022)
35. Schulman S, Lindmarker P, Holmstrom M, et al. Postthrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost 2006; 4:734-742.
36. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86:3685-3691.
37. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340:901-907. (Pubitemid 29141050)
38. Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost 2004; 2:743-749. (Pubitemid 40192487)
39. Rodger MA, Kahn PS, Wells DA, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179:417-426.
40. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: part 2. Thromb Haemost 1996; 76:824-834. (Pubitemid 27013616)
41. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115:2292-2299.